Q32 Bio (QTTB) Share-based Compensation (2017 - 2026)

Q32 Bio's Share-based Compensation history runs 10 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 406.71% year-over-year to $6.8 million in Q1 2026; TTM through Mar 2026 was $6.8 million, a 28.04% increase from a year earlier, with the FY2025 full-year figure at $5.3 million, down 58.29% from the prior year.
• Share-based Compensation rose to $6.8 million in Q1 2026 per QTTB's latest filing, from $1.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $8.4 million in Q3 2025 and bottomed at $296000.0 in Q1 2023.
• The 5-year median for Share-based Compensation is $1.3 million (2025), against an average of $2.2 million.
• Across the five-year window, Share-based Compensation tumbled 92.69% in 2023 and soared 507.81% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $3.1 million in 2022, then plunged by 83.13% to $521000.0 in 2023, then jumped by 140.12% to $1.3 million in 2024, then advanced by 17.43% to $1.5 million in 2025, then jumped by 362.9% to $6.8 million in 2026.
• Per Business Quant, the three latest QTTB Share-based Compensation figures stand at $6.8 million (Q1 2026), $1.5 million (Q4 2025), and $8.4 million (Q3 2025).